Company / Free Cash Flow
Sarepta Therapeutics Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$307.5M
FY2025
5-year range
-$577.1M / $25.3M
FY2021-FY2025
Trend
+10.3%
vs FY2024
Sector context
#169 of 194
Health Care
What the data says
Sarepta Therapeutics's free cash flow of -$307M is lower than 87% of companies in the Health Care sector (FY2025). Free Cash Flow has fluctuated over the past 10 years, ranging from -$577M in FY2023 to $25M in FY2022.
Based on SEC 10-K filings.
-$307M in FY2025.
Improved from -$577M to -$307M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 194This company -$307.5M Sector average $470.6M
▼
-165.3% below sector average
Key checks
Key Insights
- In FY2025, free cash flow increased 10.3% year-over-year.
- Ranks #169 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$307.5M | +10.3% |
| FY2024 | -$342.7M | +40.6% |
| FY2023 | -$577.1M | -2384.3% |
| FY2022 | $25.3M | +105.2% |
| FY2021 | -$481.7M | -7.1% |
| FY2020 | -$449.8M | -84.4% |
| FY2019 | -$244.0M | +45.8% |
| FY2018 | -$449.8M | -84.4% |
| FY2017 | -$244.0M | +2.9% |
| FY2016 | -$251.2M | -64.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026